Jack Geduldig
Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital
Papers
5
Total Citations
28
H-Index
3
About
Jack Geduldig is a urologic surgeon and researcher whose work centers on optimizing outcomes for patients undergoing robot-assisted radical cystectomy (RARC) for bladder cancer. His primary research areas include venous thromboembolism (VTE) prophylaxis, postoperative complication management, and the integration of novel biomarkers into surgical care. Geduldig’s major contributions include demonstrating the safety and efficacy of oral apixaban over injectable enoxaparin for VTE prevention after RARC, a finding that has practical implications for patient comfort and care protocols (15 citations). He has also compared extended versus limited thromboprophylaxis regimens and assessed complication rates following immunotherapy-based neoadjuvant treatment, providing critical data for evolving perioperative strategies. His work on circulating tumor DNA (ctDNA) in patients with positive lymph node disease highlights his interest in precision oncology. With over 28 citations across his most-cited papers, Geduldig is shaping evidence-based practices in robotic urologic surgery, particularly in the areas of thromboprophylaxis and the safe adoption of novel therapies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5